NYSE:TAKTakeda Pharmaceutical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Takeda Pharmaceutical Co Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.43 +0.84 (+5.76 %) (As of 04/6/2020 03:07 PM ET) Add Compare Share Today's Range$15.21Now: $15.43▼$15.5050-Day Range$13.02MA: $16.71▼$20.0952-Week Range$12.43Now: $15.43▼$20.92Volume925,491 shsAverage Volume2.42 million shsMarket Capitalization$48.65 billionP/E Ratio59.35Dividend Yield4.11%Beta0.92 ProfileAnalyst RatingsAdvanced ChartEarningsInstitutional OwnershipHeadlinesOptions ChainSocial Media Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. The company has a collaboration agreement with Lupus Therapeutics Inc. to evaluate the investigational biologic TAK-079 as a potential new therapy for Lupus in a Phase 1 trial. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingTakeda Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.75, Takeda Pharmaceutical has a potential upside of 60.4% from its current price of $15.43.Amount of Analyst CoverageTakeda Pharmaceutical has only been the subject of 1 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesTakeda Pharmaceutical has received 87 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTakeda Pharmaceutical has received 115 “underperform” votes. (Add your “underperform” vote.)Community SentimentTakeda Pharmaceutical has received 56.93% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Takeda Pharmaceutical and other stocks. Vote “Outperform” if you believe TAK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TAK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 2.5 Dividend Strength Dividend LeadershipTakeda Pharmaceutical is a leading dividend payer. It pays a dividend yield of 4.11%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthTakeda Pharmaceutical has only been increasing its dividend for 2 years.Dividend CoverageThe dividend payout ratio of Takeda Pharmaceutical is 117.65 %. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 28.30 % next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Takeda Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 4.16% of the stock of Takeda Pharmaceutical is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Takeda Pharmaceutical are expected to grow by 14.59% in the coming year, from $1.85 to $2.12 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Takeda Pharmaceutical is 59.35, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 11.76.Price to Earnings Ratio vs. SectorThe P/E ratio of Takeda Pharmaceutical is 59.35, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.72.Price to Book Value per Share RatioTakeda Pharmaceutical has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.2Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.84 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:TAK Previous Symbol CUSIPN/A CIKN/A Webhttp://www.takeda.com/ Phone813-3278-2306Debt Debt-to-Equity Ratio0.95 Current Ratio1.18 Quick Ratio0.81Price-To-Earnings Trailing P/E Ratio59.35 Forward P/E Ratio8.34 P/E GrowthN/A Sales & Book Value Annual Sales$18.88 billion Price / Sales2.58 Cash Flow$2.32 per share Price / Cash Flow6.64 Book Value$29.75 per share Price / Book0.52Profitability EPS (Most Recent Fiscal Year)$0.51 Net Income$982.13 million Net Margins2.25% Return on Equity13.17% Return on Assets4.89%Miscellaneous Employees49,578 Outstanding Shares3,152,750,000Market Cap$48.65 billion Next Earnings Date5/12/2020 (Estimated) OptionableOptionable Receive TAK News and Ratings via Email Sign-up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. TAK Rates by TradingView Takeda Pharmaceutical (NYSE:TAK) Frequently Asked Questions How has Takeda Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)? Takeda Pharmaceutical's stock was trading at $17.15 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TAK shares have decreased by 10.0% and is now trading at $15.43. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Takeda Pharmaceutical? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Takeda Pharmaceutical. When is Takeda Pharmaceutical's next earnings date? Takeda Pharmaceutical is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Takeda Pharmaceutical. How were Takeda Pharmaceutical's earnings last quarter? Takeda Pharmaceutical Co Ltd (NYSE:TAK) issued its quarterly earnings data on Tuesday, February, 4th. The company reported $0.53 earnings per share for the quarter. The company earned $7.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 2.25% and a return on equity of 13.17%. View Takeda Pharmaceutical's earnings history. What guidance has Takeda Pharmaceutical issued on next quarter's earnings? Takeda Pharmaceutical updated its FY 2019 Pre-Market earnings guidance on Tuesday, February, 4th. The company provided earnings per share guidance of 3.53-3.72 for the period. The company issued revenue guidance of $30.147-30.147 billion. What price target have analysts set for TAK? 4 analysts have issued 1 year price objectives for Takeda Pharmaceutical's stock. Their forecasts range from $19.50 to $30.00. On average, they anticipate Takeda Pharmaceutical's share price to reach $24.75 in the next twelve months. This suggests a possible upside of 60.4% from the stock's current price. View analysts' price targets for Takeda Pharmaceutical. Has Takeda Pharmaceutical been receiving favorable news coverage? Media coverage about TAK stock has been trending very negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Takeda Pharmaceutical earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutTakeda Pharmaceutical. Who are some of Takeda Pharmaceutical's key competitors? Some companies that are related to Takeda Pharmaceutical include Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), Sanofi (SNY), AbbVie (ABBV), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Allergan (AGN), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN) and Bayer (BAYRY). What other stocks do shareholders of Takeda Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Alibaba Group (BABA), Verizon Communications (VZ), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Walt Disney (DIS), Honeywell International (HON), NVIDIA (NVDA), CVS Health (CVS), Home Depot (HD) and Altria Group (MO). Who are Takeda Pharmaceutical's key executives? Takeda Pharmaceutical's management team includes the following people: Mr. Christophe Weber, Pres, CEO & Representative Director (Age 53)Dr. Andrew S. Plump, Chief Medical & Scientific Officer and Director (Age 54)Dr. Seigo Izumo M.D., Chair of Management BoardMr. Costa Saroukos, Chief Financial Officer (Age 48)Mr. Haruhiko Hirate, Member of Management Board & Corp. Communications and Public Affairs Officer (Age 62) What is Takeda Pharmaceutical's stock symbol? Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK." Who are Takeda Pharmaceutical's major shareholders? Takeda Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional shareholders include CLARET ASSET MANAGEMENT Corp (0.00%). Which major investors are selling Takeda Pharmaceutical stock? TAK stock was sold by a variety of institutional investors in the last quarter, including CLARET ASSET MANAGEMENT Corp. How do I buy shares of Takeda Pharmaceutical? Shares of TAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Takeda Pharmaceutical's stock price today? One share of TAK stock can currently be purchased for approximately $15.43. How big of a company is Takeda Pharmaceutical? Takeda Pharmaceutical has a market capitalization of $48.65 billion and generates $18.88 billion in revenue each year. The company earns $982.13 million in net income (profit) each year or $0.51 on an earnings per share basis. Takeda Pharmaceutical employs 49,578 workers across the globe. View additional information about Takeda Pharmaceutical. What is Takeda Pharmaceutical's official website? The official website for Takeda Pharmaceutical is http://www.takeda.com/. How can I contact Takeda Pharmaceutical? Takeda Pharmaceutical's mailing address is 1-1 Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo M0, 103-8668. The company can be reached via phone at 813-3278-2306. This page was last updated on 4/6/2020 by MarketBeat.com StaffFeatured Article: What strategies should day traders use to execute a trade?
